Trial Profile
SOLE Estrogen Substudy (SOLE-EST) - Investigating Changes in Estrogen Levels and Grip Strength for Patients Participating in the SOLE Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Aug 2022
Price :
$35
*
At a glance
- Drugs Letrozole (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms SOLE-EST
- 12 Feb 2021 Status changed from active, no longer recruiting to completed.
- 14 Dec 2019 Results presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 15 Mar 2019 Planned End Date changed from 1 Dec 2020 to 1 Apr 2020.